Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effects of Evolocumab on Endothelial and Inflammatory Biocellular Markers in Patients With Diabetes and Atherosclerotic Vascular Disease (METCHNIKOFF)

NCT03829046 is registered in ClinicalTrials.gov with Robert Rosenson as lead sponsor.

NCT NCT03829046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03829046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effects of Evolocumab on Endothelial and Inflammatory Biocellular Markers in Patients With Diabetes and Atherosclerotic Vascular Disease (METCHNIKOFF)
Lead sponsor
Robert Rosenson
Phase
Phase 4
Overall status
Completed
Start date
June 3, 2019
Completion date
November 15, 2021
Enrollment
41 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerotic vascular disease, microvascular dysfunction, type2 diabetes